• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Pennsaid (diclofenac sodium topical solution)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Pennsaid (diclofenac sodium topical solution)

  • Profile

Profile

Contact Information

Contact: Horizon
Website: https://www.pennsaid.com/

Currently Enrolling Trials

    Show More

    General Information

    Pennsaid is a topical formulation of diclofenac sodium in a patented carrier solution. The drug combines a transdermal carrier with diclofenac sodium, a nonsteroidal anti-inflammatory drug, and delivers the active drug through the skin directly to the pain site.

    Pennsaid is specifically indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s).

    Mechanism of Action

    Pennsaid is a topical formulation of diclofenac sodium in a patented carrier solution. The mechanism of action of diclofenac is similar to that of other nonsteroidal anti-inflammatory drugs. Diclofenac inhibits the enzyme cyclooxygenase (COX), an early component of the arachidonic acid cascade, resulting in the reduced formation of prostaglandins thromboxanes and prostacylin. It is not completely understood how reduced synthesis of these compounds results in therapeutic efficacy.

    Side Effects

    Adverse events associated with the use of Pennsaid may include, but are not limited to, the following:

    • Dry skin (application site)
    • Contact dermatitis (application site)
    • Dyspepsia
    • Abdominal pain
    • Flatulence
    • Pruritus (application site)
    • Diarrhea
    • Nausea
    • Pharyngitis

    Dosing/Administration

    Pennsaid is supplied as a 1.5 percent solution designed for topical administration. The recommended initial dose of the drug is 40 drops per knee, four times a day. Pennsaid should be spread evenly around front, back and sides of the knee, 10 drops at a time. Repeat this procedure until 40 drops have been applied and the knee is completely covered with solution.

    Clinical Trial Results

    FDA Approval
    The FDA approval of Pennsaid was based on two double-blind controlled trials conducted in the U.S. and Canada. The subjects were treated with placebo, another NSAID or Pennsaid Topical Solution at a dose of 40 drops four times a day for 12 weeks. In both trials, Pennsaid treatment resulted in statistically significant clinical improvement compared to placebo and/or vehicle, in all three primary efficacy variables: pain (WOMAC pain score), physical function (WOMAC physical function) and patient overall health assessment (POHA). The results were as follows:

    Study One
    WOMAC pain score: Baseline score: 13. After 12 weeks of treatment, the mean change in score was -6.0 (Pennsaid); -4.7 (placebo) and -4.7 (vehicle).
    WOMAC physical baseline score: 42. After 12 weeks of treatment, the mean change in score was -15.7 (Pennsaid); -12.3 (placebo) and -12.1 (vehicle).
    POHA baseline score: 2.3. After 12 weeks of treatment, the mean change in score was -1.0 (Pennsaid); -0.4 (placebo) and -0.6 (vehicle).

    Study Two
    This study only compared Pennsaid to an NSAID. WOMAC pain score: Baseline score: 13. After 12 weeks of treatment, the mean change in score was -5.9 (Pennsaid); -4.4 (vehicle).
    WOMAC physical baseline score: 42. After 12 weeks of treatment, the mean change in score was -15.3 (Pennsaid) and -10.3 (vehicle).
    POHABaseline score: 3.1 After 12 weeks of treatment, the mean change in score was -1.3 (Pennsaid) and -1.0 (vehicle).

    Approval Date: 2009-11-01
    Company Name: Nuvo Research
    Back to Listings

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing